Delivery Order SPE2DB20D1100-SPE2DB25FE1BW
- Not listed
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order valued at $40,205.76 to AmerisourceBergen Drug Corp on September 15, 2025, with an ultimate completion date of September 16, 2025. This firm fixed-price delivery order, issued without a set-aside designation, represents a competitive award to the pharmaceutical distributor for medical supply fulfillment. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $6,833.83 on September 2, 2025, for Pegasys 180 mcg/mL vials to support the Defense Logistics Agency's Medical Supply Chain. This competitively awarded, firm fixed-price delivery order is scheduled for completion by September 3, 2025, with performance taking place at the contractor's Conshohocken facility. The award carries no set-aside...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor based in Conshohocken, Pennsylvania, was awarded a delivery order valued at $20,168.26 by the Defense Logistics Agency's Medical Supply Chain on September 3, 2025, with an ultimate completion date of September 4, 2025. This firm fixed price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which is valued at $999,999,999.00 and extends...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order valued at $12,348.63 to AmerisourceBergen Drug Corp on August 4, 2025, under a firm fixed-price contract with an ultimate completion date of August 5, 2025. This non-set-aside delivery order was competitively awarded and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a potential value of $999,999,999...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $12,116.16 by the Defense Logistics Agency's Medical Supply Chain on July 28, 2025, with an ultimate completion date of July 29, 2025. This firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The award was...
- The Defense Logistics Agency awarded a $16,035.05 delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Qualipita 60 mg tablets (30-count packages). This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999.9 million through December 2026. The pharmaceutical will be supplied from the contractor's facility in...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $10,543.70 by the Defense Logistics Agency on September 11, 2025, with completion expected by October 2, 2025. The contract calls for the supply of Lynparza 100 mg tablets in quantities of 60 units, a targeted oncology medication used in cancer treatment. The award was made on a firm fixed-price basis without set-aside designation, indicating...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a firm fixed-price delivery order valued at $10,136.00 by the Defense Logistics Agency's Medical Supply Chain on August 19, 2025, with completion targeted for August 20, 2025. This non-set-aside contract represents a child award under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive $999.99 billion prime vendor agreement running through December...
- The Defense Logistics Agency's Medical Supply Chain has awarded a delivery order valued at $10,805.30 to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider headquartered in Conshohocken, Pennsylvania. This firm fixed price delivery order, issued on June 20, 2025, with an ultimate completion date of June 23, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX),...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $18,094.80 by the Defense Logistics Agency's Medical Supply Chain on September 11, 2025. The contract, designated as a child order under a larger indefinite delivery vehicle, represents a firm fixed-price procurement with an ultimate completion date of September 12, 2025. This award was competitively awarded with no set-aside designation,...
- SPE2DB20D1100Indefinite Delivery Contract
- SPE2DB20D1100-SPE2DB25FE1BWDelivery Order
The Defense Logistics Agency awarded a $20,286 delivery order to AmerisourceBergen Drug Corp for Pemazyre 13.5 mg tablets (quantity 14) under a firm fixed-price contract. The award, issued on September 25, 2025, has an ultimate completion date of October 17, 2025, and represents a non-set-aside competitive award. AmerisourceBergen's corporate office in Conshohocken, Pennsylvania will serve as the place of performance. This delivery order is a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive $999.999 billion vehicle running through December 2026 that provides global pharmaceutical support for military healthcare programs. AmerisourceBergen Drug Corp is a major pharmaceutical distributor serving as a critical federal medical procurement vendor, particularly for military and veteran healthcare systems. The company's DLA Troop Support Medical IDC enables supply of a broad range of pharmaceutical products and medical supplies across multiple therapeutic domains to support Defense Health Agency operations and other government healthcare systems. The current award for Pemazyre, a specialty oncology medication, exemplifies the company's role in fulfilling federal pharmaceutical needs through the DLA's medical supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $20.3k | 9/25/25 |